HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 46, 2009, Pages 19539-19544

  Iwatani, Yasumasa ^a,b,c   Chan, Denise S B ^d,e   Liu, Lin ^d   Yoshii, Hiroaki ^a   Shibata, Junko ^a   Yamamoto, Naoki ^c   Levin, Judith G ^f   Gronenborn, Angela M ^d   Sugiura, Wataru ^a,b,c  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Antiviral; Deaminase; Structure model

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CULLIN; CULLIN 5; CYTIDINE DEAMINASE; LYSINE; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VIF PROTEIN; APOBEC3G PROTEIN, HUMAN; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; COEVOLUTION; COMPLEX FORMATION; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; UBIQUITINATION; VIRUS INHIBITION; VIRUS REPLICATION; CELL LINE; CHEMISTRY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CELL LINE; CYTIDINE DEAMINASE; HIV INFECTIONS; HIV-1; HUMANS; LYSINE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; UBIQUITINATION; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 73349120299     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0906652106     Document Type: Article

References (48)

1. Holmes RK, Malim MH, Bishop KN (2007) APOBEC-mediated viral restriction: Not simply editing? Trends Biochem Sci 32:118-128.
2. Wedekind JE, Dance GS, Sowden MP, Smith HC (2003) Messenger RNA editing in mammals: New members of the APOBEC family seeking roles in the family business. Trends Genet 19:207-216.
3. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
4. Conticello SG, Harris RS, Neuberger MS (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 13:2009-2013.
5. Marin M, Rose KM, Kozak SL, Kabat D (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9:1398-1403.
6. Mehle A, et al. (2004) Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 279:7792-7798.
7. Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9:1404-1407.
8. Stopak K, de Noronha C, Yonemoto W, Greene WC (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12:591-601.
9. Yu X, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060.
10. Henriet S, et al. (2009) Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev 73:211-232.
11. Goila-Gaur R, Strebel K (2008) HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5:51.
12. Iwatani Y, et al. (2007) Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res 35:7096-7108.
13. Miyagi E, et al. (2007) Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol 81:13346-13353.
14. Bishop KN, et al. (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4:e1000231.
15. Nathans R, et al. (2008) Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol 26:1187-1192.
16. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425-479.
17. Pickart CM (2001) Mechanisms underlying ubiquitination. Annu Rev Biochem 70:503-533.
18. Skowyra D, et al. (1997) F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91:209-219.
19. Mehle A, et al. (2004) Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev 18:2861-2866.
20. Stanley BJ, et al. (2008) Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J Virol 82:8656-8663.
21. Kobayashi M, et al. (2005) Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function. J Biol Chem 280:18573-18578.
22. Mehle A, Thomas ER, Rajendran KS, Gabuzda D (2006) A zinc-binding region in Vif binds Cul5 and determines cullin selection. J Biol Chem 281:17259-17265.
23. Xiao Z, et al. (2006) Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349:290-299.
24. Pery E, Rajendran KS, Brazier AJ, Gabuzda D (2009) Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J Virol 83:2374-2381.
25. Russell RA, et al. (2009) Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol 83:1992-2003.
26. Schröfelbauer B, Senger T, Manning G, Landau NR (2006) Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J Virol 80:5984-5991.
27. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA 101:3770-3774.
28. Mangeat B, Turelli P, Liao S, Trono D (2004) A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem 279:14481-14483.
29. Schröfelbauer B, Chen D, Landau NR (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci USA 101:3927-3932.
30. Xu H, et al. (2004) A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci USA 101:5652-5657.
31. Huthoff H, Malim MH (2007) Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J Virol 81:3807-3815.
32. Holden LG, et al. (2008) Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456:121-124.
33. Prochnow C, et al. (2007) The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature 445:447-451.
34. Eswar N, et al. (2006) Comparative protein structure modeling using Modeller. Curr Protoc Bioinformatics Chapter 5:Unit 5 6.
35. Kao S, et al. (2003) The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol 77:11398-11407.
36. Xu H, et al. (2007) Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 360:247-256.
37. Chen KM, et al. (2008) Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452:116-119.
38. Furukawa A, et al. (2009) Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. EMBO J 28:440-451.
39. Harjes E, et al. (2009) An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J Mol Biol 389:819-832.
40. Huthoff H, et al. (2009) RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog 5:e1000330.
41. Zhang KL, et al. (2007) Model structure of human APOBEC3G. PLoS ONE 2:e378.
42. Dang Y, Siew LM, Zheng YH (2008) APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated. J Biol Chem 283:13124-13131.
43. Gooch BD, Cullen BR (2008) Functional domain organization of human APOBEC3G. Virology 379:118-124.
44. Zheng N, et al. (2002) Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 416:703-709.
45. Scherer DC, et al. (1995) Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci USA 92:11259-11263.
46. Stroschein SL, Bonni S, Wrana JL, Luo K (2001) Smad3 recruits the anaphase-promoting complex for ubiquitination and degradation of SnoN. Genes Dev 15:2822-2836.
47. Orlicky S, et al. (2003) Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase. Cell 112:243-256.
48. Iwatani Y, Takeuchi H, Strebel K, Levin JG (2006) Biochemical activities of highly purified, catalytically active human APOBEC3G: Correlation with antiviral effect. J Virol 80:5992-6002.